RNASE2 and neoplasm: Despite convincing preclinical evidence for a range of different tumour types (reviewed in Nelson et al, 2003), most clinical studies in the field of oncology to date have not shown significant benefit of EDN inhibition (Rosano et al, 2013), suggesting that a deeper molecular and system‐oriented understanding of EDN signalling is required to devise more promising, knowledge‐based treatment strategies, e.g. through matching specific drug combinations with patient subgroups.